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most aggressive squamous cell carcinomas and is highly
prevalent in Asia. Alcohol and its metabolite, acetaldehyde,
are considered deﬁnite carcinogens for the esophagus.
Polymorphisms in the aldehyde dehydrogenase 2 gene,
which encodes an enzyme that eliminates acetaldehyde,
have been associated with esophageal carcinogenesis.
Studies of the mutagenic and carcinogenic effects of acet-
aldehyde support this observation. Several recent large-
scale comprehensive analyses of the genomic alterations
in ESCC have shown a high frequency of mutations in genes
such as TP53 and others that regulate the cell cycle or cell
differentiation. Moreover, whole genome and whole exome
sequencing studies have frequently detected somatic mu-
tations, such as G:C/A:T transitions or G:C/C:G trans-
versions, in ESCC tissues. Genomic instability, caused by
abnormalities in the Fanconi anemia DNA repair pathway,
is also considered a pathogenic mechanism of ESCC.
Advances in diagnostic techniques such as magnifying
endoscopy with narrow band imaging or positron emission
tomography have increased the accuracy of diagnosis of
ESCC. Updated guidelines from the National Comprehen-
sive Cancer Network standardize the practice for the
diagnosis and treatment of esophageal cancer. Patients
with ESCC are treated endoscopically or with surgery,
chemotherapy, or radiotherapy, based on tumor stage.
Minimally invasive treatments help improve the quality of
life of patients who undergo such treatments. We review
recent developments in the diagnosis and treatment of
ESCC and advances gained from basic and clinical research.Abbreviations used in this paper: ADH1B, alcohol dehydrogenase 1B;
ALDH2, aldehyde dehydrogenase 2; CRT, chemoradiotherapy; CT,
computed tomography; CYP, cytochrome P450; DCF, docetaxel and
cisplatin plus 5-ﬂuorouracil; dG, deoxyguanosine; EGFR, epidermal
growth factor receptor; ER, endoscopic resection; ESCC, esophageal
squamous cell carcinoma; EUS, endoscopic ultrasonography; FA, Fanconi
anemia; FDG-PET, 18F-ﬂuorodeoxyglucose positron emission tomogra-Keywords: Acetaldehyde; Aldehyde Dehydrogenase 2; Genetic
Polymorphism; Field Cancerization; Squamous Differentiation.
sophageal cancer is the 8th most common cancerphy; 5-FU, 5-ﬂuorouracil; GST, glutathione S-transferase; HGIN,
high-grade intraepithelial neoplasia; HPV, human papillomavirus; IPCL,
intrapapillary capillary loop; LGIN, low-grade intraepithelial neoplasia;
LVL, Lugol-voiding lesion; NBI, narrow band imaging; SCC, squamous cell
carcinoma; SEMS, self-expanding metal stent.
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Open access under CC BY-NC-ND license.Eand the 6th leading cause of cancer-related mortality
in the world,1–3 with an estimated 456,000 new cases per
year worldwide.3 Esophageal cancer comprises 2 main his-
tological subtypes: esophageal squamous cell carcinoma
(ESCC) and esophageal adenocarcinoma.4 ESCC is the major
histological type and accounts for 80% of cases of esopha-
geal cancer worldwide.2 The incidence of ESCC is high in
speciﬁc ethnic groups and certain locations5,6 and is affectedby environmental factors (alcohol consumption and tobacco
use) and genetic factors (mutations in enzymes that
metabolize alcohol).1
Only 15% to 25% of patients with ESCC survive for 5
years after diagnosis.7,8 Recent advances in image-enhanced
endoscopy allow detection of early esophageal neoplastic
lesions.9 Advances in therapeutics such as endoscopic
resection (ER), surgery, radiotherapy, and chemotherapy
have led to substantial improvements in clinical management
and outcomes.1,7 We review recent multidisciplinary ad-
vances in basic and clinical studies of ESCC.
Epidemiology
The incidence of esophageal cancer is 3-fold higher in
men than women,3 and approximately 80% of cases occur in
developing countries.3 The incidence of esophageal cancer
varies greatly with location.5 There is a high prevalence of
ESCC in east Asia, eastern and southern Africa, and southern
Europe.5,10 In contrast, the incidence of ESCC is low in North
America and other parts of Europe.6 These variations indi-
cate that ethnic and genetic factors and lifestyle all have
roles in the development of ESCC.
Alcohol consumption and tobacco use are established
risk factors for ESCC7 and have synergistic effects on risk.11
Acetaldehyde associated with alcohol intake was added as a
deﬁnite carcinogen (a group 1 carcinogen) for the esoph-
agus by the International Agency for Research on Cancer.12
Purported risk factors for ESCC include low levels of con-
sumption of fruits and vegetables; deﬁciency of selenium,
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ESzinc, or vitamin E; high levels of exposure to areca nuts or
polycystic aromatic hydrocarbons; and poor oral hy-
giene.1,12 Meta-analyses have found evidence for the
involvement of human papillomavirus (HPV) infection in
ESCC.13,14
Alcohol, Acetaldehyde, and
Carcinogenesis
Ingested alcohol is absorbed from the upper gastroin-
testinal tract and transported to the liver, where it is
metabolized to acetaldehyde (intrinsic acetaldehyde) by
alcohol dehydrogenase 1B (ADH1B). Acetaldehyde is sub-
sequently detoxiﬁed to acetic acid by aldehyde dehydroge-
nase 2 (ALDH2) (Figure 1).15 ALDH2 activity is reduced by
the polymorphism Glu504Lys,16 which is prevalent in
Mongoloid but not in Caucasoid or Negroid populations17; it
increases blood, salivary, and breath levels of acetaldehyde
after alcohol intake.18,19 Heavy ingestion of alcohol in-
creases the risk of ESCC in people with the ALDH2
Glu504Lys polymorphism.20 This ﬁnding could account for
the higher incidence of ESCC in Asian versus Western
countries.
Acetaldehyde is an organic compound found in ripe
fruits, bread, coffee, cheese, and yogurt,21 alcoholic bever-
ages,21 and tobacco smoke.22 Alcoholic beverages such as
Calvados and other spirits contain particularly high amounts
of acetaldehyde, and frequent consumption of these bever-
ages is associated with an increased risk of ESCC.23 Acetal-
dehyde can also be generated in the human oral cavity by
microorganisms such as yeasts and bacteria.24–26 Acetalde-
hyde from alcoholic beverages, foods, and/or oral micro-
ﬂora could therefore provide a potential source of
carcinogens that predispose people to ESCC (Figure 1).
Numerous in vitro and in vivo studies support the
mutagenic and carcinogenic effects of acetaldehyde.27
Acetaldehyde causes single- and double-strand DNA
breaks,28 point mutations,29 sister chromatid exchanges,
and gross chromosomal aberrations.30,31 Acetaldehyde also
binds to proteins to cause structural and functional alter-
ations.27 Many of the altered enzymes are involved in DNA
repair, DNA methylation, and the antioxidative defense
system.32,33 Studies of inhalation in rats and hamsters show
that acetaldehyde causes nasal carcinoma and respiratory
squamous cell carcinoma (SCC).34,35
Acetaldehyde reacts with DNA to form DNA adducts.36 A
single molecule of acetaldehyde reacts with deoxyguanosine
(dG) to generate N2-ethylidene-20-dG, which can be stabi-
lized by reduction to the product N2-ethyl-20-dG
(Figure 2).36 Because N2-ethylidene-20-dG is the direct and
most abundant DNA adduct derived from acetaldehyde, it is
a speciﬁc biomarker for identifying acetaldehyde-derived
DNA damage.37 N2-ethyl-20-dG inhibits trans-lesion DNA
synthesis, which leads to replication errors and/or frame-
shift deletion mutations.38 Another class of DNA adducts,
N2-propano-20-dG, which is derived from 2 molecules of
acetaldehyde (Figure 2), has also been shown to be muta-
genic.39,40 However, the mechanistic role of DNA adducts in
acetaldehyde-related ESCC carcinogenesis is unclear.36Exposure of human normal ﬁbroblasts to acetaldehyde
induces mutations (most frequently G:C/A:T transitions)
in the tumor suppressor gene TP53.41 This transition
pattern is consistent with that found in a study of the HPRT
reporter gene.29 Additionally, the G:C/T:A transition is the
second most frequent acetaldehyde-mediated mutation in
TP53, indicating that G:C base pairs are a speciﬁc target of
acetaldehyde-induced damage.41 Given that acetaldehyde
reacts with dG to generate DNA adducts such as N2-ethyl-
idene-20-dG and N2-propano-20-dG, guanine might be a
speciﬁc target of acetaldehyde. These ﬁndings support the
idea that exposure to acetaldehyde contributes to develop-
ment of ESCC.Tobacco and Carcinogenesis
A large-scale, population-based cohort study revealed
that past smokers (adjusted hazard ratio, 3.27) as well as
current smokers (adjusted hazard ratio, 3.69) have a higher
risk of ESCC than never smokers.42 Among current smokers,
pack-years and cigarettes per day are also associated with
the incidence of ESCC, with the risk increasing in a dose-
dependent manner.42
Tobacco smoke contains carcinogenic substances such as
nicotine-derived nitrosamine ketone and N0-nitrosonornicotine,
which are called tobacco-speciﬁc nitrosamines43; direct
contact between these carcinogens and the esophageal
mucosa has been proposed to increase the risk of ESCC.
Polycyclic aromatic hydrocarbons and aromatic amines are
also major classes of carcinogens present in tobacco and
tobacco smoke.44 They are converted into DNA-reactive
metabolites by cytochrome P450 (CYP)-related enzymes
and then subjected to detoxiﬁcation by glutathione S-
transferases (GSTs).44 Genetic polymorphisms of these
enzymes (eg, CYP1A1,45–47 GSTM1,45 and GSTP148) have
been associated with the risk of esophageal cancer,49 and
a meta-analysis revealed that people with Ile to Val sub-
stitution encoded in the CYP1A1 gene have an increased
risk of esophageal cancer.50 Tobacco smoke contains the
carcinogen acetaldehyde,51 so alcohol consumption and
tobacco smoking are considered to increase the risk of
ESCC synergistically in people with speciﬁc poly-
morphisms in ADH1B and ALDH2.52Development of ESCC
ESCC develops via a multistep process that begins with a
normal squamous epithelium and progresses to low-grade
intraepithelial neoplasia (LGIN), high-grade intraepithelial
neoplasia (HGIN), and ultimately to invasive carcinoma
(Figure 3A).53 LGIN, HGIN, and invasive ESCC can be visu-
alized as Lugol-voiding lesions (LVLs) by Lugol chro-
moendoscopy.54,55 The staining pattern of LVLs varies from
an absence of LVLs to numerous irregularly shaped multi-
form LVLs (Figure 3B).
ESCC occurs synchronously and/or metachronously in
conjunction with head and neck SCC. This association can be
explained by the phenomenon of ﬁeld cancerization.56 A
polyclonal mutation in p53 is believed to be a mechanism
Figure 1. The source of acetaldehyde. The esophageal epithelium is exposed to carcinogenic acetaldehyde via (1) intrinsic and (2)
extrinsic pathways. (1) Intrinsic acetaldehyde derived from ethanol metabolism in the liver. Ethanol is absorbed in the upper
gastrointestinal tract and ismetabolized to acetaldehyde by ADH1B in the liver. Subsequently, acetaldehyde is degraded to acetic
acid by ALDH2. Acetaldehyde that exceeds its degrading activity in the liver circulates throughout the entire body, including the
esophagus, lungs, and salivaryglands. (2) Extrinsicacetaldehydederived fromalcoholicbeverages and foods (a) and thatproduced
by oral microﬂora (b). Extrinsic acetaldehyde is believed to be associated with direct exposure to the esophageal epithelium.
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Figure 2. Formation of acetaldehyde-derived DNA adducts.
A single molecule of acetaldehyde reacts with dG to form
N2-ethylidene-20-dG, which is reduced to N2-ethyl-20-dG. The
reaction of acetaldehyde with N2-ethylidene-dG results in the
formation of a-CH3-g-OH-1, N
2-propano-20-dG.
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ESinvolved in ﬁeld cancerization.57 A polymorphism in ALDH2
has also been related to the occurrence of multiple LVLs and
multiple SCCs in the esophagus and the head and neck.58
Again, acetaldehyde is considered to have a key role in
ﬁeld cancerization of the squamous epithelium.
Pathology
In histopathologic analyses, ESCC is deﬁned based
on mitotic activity, nuclear atypia, and degree of squa-
mous differentiation.53 Consequently, ESCC is classiﬁed
as well-differentiated SCC, moderately differentiated SCC,
poorly differentiated SCC, and undifferentiated SCC
(Figure 4) (World Health Organization classiﬁcations).53
The histopathologic grade is incorporated into the
TNM classiﬁcation as a factor (G categories: G1, well
differentiated; G2, moderately differentiated; G3, poorly
differentiated; G4, undifferentiated) that is used to
determine prognosis.59 Involucrin is expressed in well-
differentiated ESCC tumor nests but not in poorly
differentiated ESCC, and it is considered to be a marker
of the differentiation grade of ESCC tissues.60,61 Because
inhibition of squamous differentiation promotes tumor
development in xenograft models,60 squamous differen-
tiation might affect the malignant potential of individual
ESCC cells.Genetics
Genes that Regulate the Cell Cycle
or Differentiation
Analyses of comprehensive mutational catalogues using
high-throughput sequencing technologies have revealed
widespread genomic alterations in ESCC (Table 1).62–65 The
ﬁrst large-scale comprehensive analysis, which was con-
ducted using whole genome sequencing, whole exome
sequencing, and array-based comparative genomic hybridi-
zation, showed that more than 83% of ESCCs contained a
somatic mutation in TP53.62 The highest frequency of
mutation was in TP53 (59%–93% of all patients), conﬁrmed
by other large-scale whole genome or whole exome
sequencing analyses.63–65 Mutation of TP53 has therefore
been proposed as a key factor in the development of ESCC.
Mutations in other cell genes that regulate the cell cycle
(CDKN2A [encodes p16], RB1, NFE2L2, CHEK1, and CHEK2)
or differentiation (NOTCH1 and NOTCH3) have been detec-
ted in 2% to 10% of ESCCs.62–64 Moreover, many genes that
regulate the cell cycle are also ampliﬁed in ESCCs (CCND1 in
46.4% of cases, CDK4/CDK6 in 23.6% of cases, and MDM2 in
5.7% of cases),62 implicating them in the development of
ESCC.Epidermal Growth Factor Receptor
Signaling Pathway
Epidermal growth factor receptor (EGFR) is overex-
pressed in 59.6% to 76% of ESCCs66,67 and is associated
with a poor prognosis.66,67 Large-scale sequencing studies
have shown EGFR to be overexpressed (in 68% of tumors)
and/or ampliﬁed (in 11%–24%)62 but not frequently
mutated (in 0–1.8% of ESCCs).62–64 Moreover, 78.6% of
ESCCs have mutations and/or ampliﬁcations in factors
downstream of EGFR, such as RAS and AKT pathways.62
EGFR signaling pathways are considered to be involved in
the development of ESCC.Somatic Mutational Signature
G:C/A:T transitions and G:C/C:G transversions are
frequently detected in ESCC cells.63,65 Interestingly, the
G:C/A:T transition is a typical mutation signature induced
by acetaldehyde.29,41 Another mutation frequently detected
in ESCC is that of cytosine in TpCpX trinucleotides.65 This
pattern corresponds to the mutation signature that can be
induced by members of the APOBEC family,68,69 which
might reﬂect the increased APOBEC activity observed in
ESCC cells.Epigenetic Factors
Epigenetic alterations such as DNA methylation, histone
modiﬁcation, and loss of genome imprinting are involved in
the development of ESCC, as for other neoplasms.70 For
instance, hypermethylation of promoter regions of APC, RB1,
and CDKN2A has been detected in ESCCs.71–73 Methylation of
CDKN2A, whose product p16 regulates RB1, is associated
Figure 3. Scheme of
the dysplasia-carcinoma
sequence. (A) Images of
H&E staining in tissues
representing normal
epithelium, LGIN, HGIN,
and invasive cancer. An
increased number of basal
cells and mild cytological
atypia are seen in LGIN,
whereas architectural
disarray, loss of polarity,
and cellular atypia (greater
than that seen in LGIN) are
evident in HGIN. These
stages are considered to
develop progressively. (B)
Representative endo-
scopic views of Lugol
chromoendoscopy sho-
wing no LVLs, several
LVLs, and many irregularly
shaped multiform LVLs.
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appear to interact to promote the development of ESCC.
Mutations in genes that regulate histone modiﬁcation
have been observed in approximately 63% of ESCCs (mu-
tations in MLL2 detected in 19%, in EP300 in 10%, in MLL3
in 6%, and in CREBBP in 6%).64 In addition, members of the
SWI/SNF complex, which is involved in epigenetic regula-
tion, are mutated in ESCCs (mutations in ARID detected in
5%, in PBRM1 detected in 5%, and in ARID1A detected
in 1%).63Hereditary ESCC
Tylosis esophageal cancer, also known as Howel–Evans
syndrome, is a rare familial cancer syndrome inherited in an
autosomal dominant manner and characterized by hyper-
keratosis of the palms or soles. People with this syndrome
have a high risk of esophageal cancer.75 More than 90% ofFigure 4. Representative histopathologic images of ESCC.
ESCC is graded based on mitotic activity, nuclear atypia, and
degree of squamous differentiation. (Left panel) Well-
differentiated SCC. (Middle panel) Moderately differentiated
SCC. (Right panel) Poorly differentiated SCC.patients with this syndrome develop ESCC by the time they
are 65 years old.76 Missense mutation of rhomboid family
member gene 2 (RHBDF2), which is involved in the activa-
tion of EGFR signaling, has been found to cause this
syndrome.75Polymorphisms
Polymorphisms in genes such as TP53,77 MDM21,77
CASP8,78 and COX279 are associated with the risk of ESCC.
Recent genome-wide association study–based analyses of
patients with ESCC detected several single nucleotide
polymorphisms that appear to be risk factors for ESCC.
These include rs4135113, which regulates nonsynonymous
coding in base excision repair; rs1800450, which regulates
monosaccharide binding; and rs3769823, which regulates
CASP8.80 These single nucleotide polymorphisms are
considered to be associated with susceptibility to ESCC.80
Moreover, an integration analysis of 3 genome-wide asso-
ciation studies, comprising more than 9000 cases of ESCC,
associated the single nucleotide polymorphisms rs7447927
(located at 5q31.2) and rs1642764 (located at 17p13.1)
with ESCC.81Fanconi Anemia Pathway
Fanconi anemia (FA) is an autosomal recessive disorder
characterized by genomic instability, bone marrow failure,
developmental defects, and early development of cancers
such as hematologic malignancies and SCCs of the uterine
cervix, head and neck, and esophagus.82 FA is caused by
mutations in genes that regulate the FA pathway, which
Table 1.Recent Results of Comprehensive Analyses of Genetic Alterations Using High-Throughput Sequencing
No. of patients (method) Ethnic group Genomic alterations Authors
17 (WGS), 71 (WES), 123 (CGH) Chinese TP53, RB1, CDKN2A (p16), NFE2L2, CHEK1, CHEK2,
PIK3CA, NOTCH1, NOTCH3, CCND1, CDK4/CDK6,
MDM2, EGFR
Song et al62
20 (WES), 119 (targeted seq),
4 (RNA seq)
Chinese TP53, RB1,CDKN2A (p16), NFE2L2, PIK3CA, NOTCH1,
NOTCH3, ARID2, EGFR, RTK/RAS signaling pathways
Lin et al63
118 (WES) Chinese TP53, RB1, CDKN2A (p16), NFE2L2, CCND1, EGFR,
histone-modifying genes (MLL2, MLL3, CREBBP)
Gao et al64
14 (WGS), 90 (WES) Chinese TP53, CDKN2A (p16), PIK3CA, and mutational signature Zhang et al65
WGS, whole-genome sequencing; WES, whole-exome sequencing; CGH, comparative genomic hybridization;
seq, sequencing.
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EScontrols replicon-dependent removal of interstrand DNA
cross-links. The FA pathway is studied during research on
DNA repair, cancer progression, and protein ubiquitination
in response to genotoxic insults.83 FANCD2, a factor in the
FA pathway, counteracts acetaldehyde-induced genotoxicity
in mice.84 Moreover, germline mutations in FANCD1
(BRCA2) are also found in patients with a familial history of
ESCC.85 These results indicate that the role of the FA
pathway in ESCC caused by acetaldehyde-mediated DNA
damage.HPV
HPV promotes carcinogenesis through the action of
oncoproteins E6 and E7, which target numerous cellular
pathways, including the inactivation of p53 and retinoblas-
toma protein.86 HPV infection is associated with tumori-
genesis in cervical cancer as well as in head and neck SCC.87
However, a relationship between HPV infection and devel-
opment of ESCC has not been observed consistently.53 A
comprehensive genetic analysis found no correlation be-
tween HPV infection and ESCC.62 In contrast, a meta-
analysis reported the prevalence of HPV in patients with
ESCC to be as high as 32.2%.13 Africa and Asia have the
highest prevalence of HPV; speciﬁc Chinese provinces with a
high prevalence of HPV have a particularly high incidence of
ESCC.13 There is controversy over whether HPV infection is
associated with the development of ESCC.Mechanisms of Invasion and Metastasis
A recent study associated ampliﬁcation of the eukaryotic
initiation factor 5A2 gene (eIF5A2) with ESCC invasiveness
and metastasis of ESCC via hypoxia.88 eIF5A2 could promote
the epithelial-to-mesenchymal transition and increase the
migratory and invasive capacities of esophageal cells.88
A 3-dimensional organotypic culture system can be used
to investigate the mechanisms of invasion based on in-
teractions between the epithelium and stroma.89 Researchers
have used this model to identify several genes and signaling
pathways that regulate esophageal cell invasion. Over-
expression of EGFR and inactivation of p53 in esophageal
epithelial cells expand a cell subpopulation via upregulationof zinc ﬁnger E-box binding transcription factors that can
undergo the epithelial-to-mesenchymal transition.90 These
cells have an invasive phenotype in the stromal matrix,
accompanied by increases in activation of the RTK cMET.91,92
Moreover, microarray analysis of RNA extracted by laser
capture microdissection from invading cells grown in
3-dimensional organotypic culture, compared with non-
invading cells, identiﬁed several genes that might facilitate
tumor invasion. These genes include insulin-like growth
factor–binding protein 3,93 periostin,94 and WNT10A.95
Furthermore, stromal ﬁbroblasts regulate the invasive activ-
ities of ESCC cells; ﬁbroblast-secreted hepatocyte growth
factor, the ligand of c-MET, helps create an environment
conducive to tumor invasion.92Diagnosis and Staging
Imaging modalities such as endoscopy, endoscopic ul-
trasonography (EUS), esophagography, computed tomogra-
phy (CT), and 18F-ﬂuorodeoxyglucose positron emission
tomography (FDG-PET) are used in the diagnosis and stag-
ing of ESCC. Endoscopy is the most sensitive modality for
the detection and diagnosis of esophageal neoplasia. The use
of endoscopic screening and treatment has contributed to
reductions in ESCC-associated mortality.96 EUS, esoph-
agography, CT, and FDG-PET are used to assess the depth of
invasion in the esophageal wall, length of tumors, direct
invasion to adjacent organs, and lymph node and distant
metastasis.97Endoscopy
Advanced ESCC is found as a protruding mass or a
depressed ulcer. Superﬁcial ESCC is often difﬁcult to identify
because of minimal macroscopic and color changes, but it is
usually observed as an uneven surface with a thin white
coating or a reddish color change on the mucosal surface.98
Iodine has an afﬁnity for glycogen in the nonkeratinized
squamous epithelium and stains the normal epithelium a
mahogany brown color; the cancerous epithelium is devoid
of staining because it lacks glycogen.99 Lugol solution, which
contains iodine, was ﬁrst introduced as Schiller test for the
detection of SCC in the uterine cervix99 and is now used in
Figure 5. Diagnosis of superﬁcial ESCC using endoscopy. (A)
Lugol chromoendoscopy. Immediately after Lugol staining,
cancerous lesions are seen as LVLs. (B) Pink color sign.
Deﬁnite cancerous lesions show the pink color sign a few
minutes after Lugol staining. (C) White light imaging of su-
perﬁcial ESCC. A reddish ﬂat lesion is seen in the posterior
wall of the esophagus. (D) NBI identiﬁes the same lesion
clearly as a well-demarcated brownish area. (E) Representa-
tive images of IPCLs. Magnifying NBI showed looped IPCL
with morphological changes of dilation, meandering, irregular
caliber, and nonuniformity. These ﬁndings indicate that the
depth of the tumor is Tis or T1a lamina propria mucosa. (F)
Nonlooped IPCLs. Magnifying NBI showed nonlooped IPCL
characterized by extension and advanced destruction of
looped IPCLs and/or generation of new tumor vessel. These
ﬁndings indicate that the depth of the tumor is deeper than
T1a muscularis mucosa.
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Lugol chromoendoscopy to detect ESCC.100 The pink color
sign, a light-pink appearance of the iodine-unstained area a
few minutes after iodine staining in Lugol chromoendo-
scopy (Figure 5A and B), is also useful for distinguishing SCC
or HGIN from LGIN.101 This appearance is based on the
complete loss of the normal keratinous layers in the
mucosal layers of HGIN.101 The sensitivity and speciﬁcity of
the pink color sign for the discrimination of HGIN from LGIN
are 92% and 94%, respectively.101
A narrow band imaging (NBI) system, which uses nar-
row band illumination of 415-nm and 540-nm wavelengths
corresponding to the peaks of the absorption wavelengths
of hemoglobin,102 can detect superﬁcial ESCC as a
well-demarcated brownish area (Figure 5C and D).103
Magnifying NBI clearly visualizes microvascular structures(intrapapillary capillary loops [IPCLs]) of the squamous
epithelium and cancerous lesions (Figure 5E and F)104 and
is useful for identifying cancerous lesions by the changes in
IPCLs.104 A prospective, randomized, controlled study re-
ported a higher detection rate of superﬁcial SCC in the head
and neck and the esophagus for NBI compared with con-
ventional white light imaging (97% vs 55%).103 NBI detects
superﬁcial cancer in the head and neck with 100% sensi-
tivity, 78.6% speciﬁcity, 83.3% positive predictive value,
100% negative predictive value, and 86.7% accuracy. NBI
detects cancer of the esophagus with 97.2% sensitivity,
42.1% speciﬁcity, 90.4% positive predictive value, 72.8%
negative predictive value, and 88.9% accuracy.103Staging
Staging of the tumor is important to determine the
therapeutic strategy. The Union for International Cancer
Control TNM classiﬁcation (7th edition, 2009) is used
widely to assess the anatomic extent of ESCC.59
The T stage is deﬁned by the extent of the primary tumor
and is classiﬁed as one of 5 categories: Tis (carcinoma in
situ or high-grade dysplasia; eg, intraepithelial tumor), T1
(T1a, tumor invading the lamina propria or muscularis
mucosae; T1b, tumor invading the submucosa), T2 (tumor
invading the muscularis propria), T3 (tumor invading the
adventitia), and T4 (tumor invading the adjacent structures:
T4a, tumor invading the pleura, pericardium, or diaphragm;
T4b, tumor invading other adjacent structures such as the
aorta, vertebral body, or trachea).59 Endoscopy, EUS,
esophagography, and CT are used for T staging of tumors.
Macroscopic ﬁndings on endoscopy are useful for the
assessment of tumor depth of superﬁcial ESCC. According to
the Japanese Classiﬁcation of Esophageal Cancer,98 superﬁ-
cial (type 0) cancers are classiﬁed into types 0-I (superﬁcial
and protruding type), 0-II (superﬁcial and ﬂat type: a lesion
without deﬁnite protrusion or depression), and 0-III (su-
perﬁcial and excavated type). 0-I lesions and 0-III lesions
are believed to have high probabilities (94.7% and 100%,
respectively) of invading up to the submucosal layers (T1b
stage). Most 0-IIa (slightly elevated type) and 0-IIb (ﬂat
type) tumors are Tis or T1a cancers, whereas 0-IIc (slightly
depressed type) tumors are widely distributed from Tis to
T1b cancers.105
The depth of cancer invasion is described according to
the IPCL classiﬁcation pattern by NBI with magniﬁcation.104
Magnifying NBI can differentiate intramucosal cancers (Tis
or T1a) from submucosal (T1b) cancers with high levels of
sensitivity (78%) and speciﬁcity (95%).106 Visualization of
the microvascular structure of the tumors by magnifying
NBI is therefore a useful tool for the differential diagnosis of
T1a from T1b cancers.
Esophagography is used for evaluating the shape, length,
and location of tumor.107 EUS and CT are also used for
evaluating the T stage of ESCC. EUS can identify the distinct
tissue layers of the esophageal wall, and a tumor can be
detected as a low echoic mass. EUS using a 20- to 30-MHz
mini-probe is useful for diagnosing the tumor depth in su-
perﬁcial ESCC.108
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ESAs a limitation, EUS is unreliable for the staging of tu-
mors with stenotic lesions or after neoadjuvant chemo-
therapy.109,110 CT also has limitations for determining the
exact depth of a tumor within the esophageal wall and thus
cannot differentiate between T1, T2, and T3, although CT is
useful for discriminating T3 and T4 regions.111 The accuracy
of CT for T4b staging in terms of aortic and tracheobronchial
invasion is approximately 80%.112,113 When tracheobron-
chial invasion is suspected, bronchoscopy and biopsy should
be considered to conﬁrm the diagnosis.
N-stage tumors (spread to regional lymph nodes) are
deﬁned by the number of involved regional nodes, including
celiac axis nodes and cervical paraesophageal nodes but not
supraclavicular nodes. The categories are N0 (no regional
lymph node metastasis), N1 (metastasis in 1–2 regional
lymph nodes), N2 (metastasis in 3–6 regional lymph nodes),
and N3 (metastasis in 7 regional lymph nodes).59 EUS and
CT are used to determine the presence of involved regional
lymph nodes in patients with ESCC. In a meta-analysis to
compare the diagnostic performance of EUS and CT in N
staging, the sensitivity and speciﬁcity values for EUS were
80% and 70%, respectively; those of CT were 50% and
83%, respectively.114
M-stage tumors are classiﬁed as M0 (no distant metas-
tasis) and M1 (distant metastasis).59 Contrast-enhanced CT is
the most commonly used imaging modality to detect distant
metastasis, and masses in the liver larger than 1 cm are likely
to be hepatic metastatic lesions. The sensitivity of contrast-
enhanced CT for detecting metastasis is as high as 90%.115
FDG-PET is of value in the detection of distant metastasis
at the initial staging of esophageal cancer as well as in the
assessment of the response to induction chemo-
therapy.116,117 However, FDG-PET has a low sensitivity for
initial nodal staging,116 and it is unclear whether FDG-PET is
useful in the assessment of recurrence after surgery.118
Recently, coregistration of FDG-PET and CT using a com-
bined system has been shown to be of additional value for
image interpretation using both modalities.118 This dual-
imaging modality allows clinicians to evaluate tumors
functionally and structurally,119 improves the accuracy of
FDG-PET imaging in esophageal cancer, and provides useful
data of diagnostic and therapeutic signiﬁcance for clinical
management.118
Treatment
There are many different approaches to the treatment of
patients with ESCC, including endoscopic therapy, surgery,
chemotherapy, and radiotherapy. To facilitate the standard
practice of therapeutics based on the principle of evidence-
based medicine, updated guidelines for esophageal cancers
are published by the National Comprehensive Cancer
Network.97 The Japan Esophageal Society has also edited
guidelines for the diagnosis and treatment of esophageal
carcinoma.120
Endoscopic Resection and Ablation
Early-stage ESCC (Tis and T1a), with negligible risk of
metastasis to the lymph node, can be cured by endoscopiclocal treatment, such as ER and/or an ablative method (eg,
radiofrequency ablation or photodynamic therapy).97 Before
endoscopic treatment, the depth of invasion, horizontal
spread, and presence or absence of multifocal lesions should
be characterized fully. The depth of invasion is closely
associated with lymph node metastasis, and the frequency
of lymph node metastasis in mucosal ESCC is reported to be
3%.121 However, the accuracy of pretreatment diagnosis
regarding the depth of invasion using EUS and/or magni-
fying NBI is limited. To accurately determine the depth of
invasion, diagnostic ER can be used. Endoscopic submucosal
dissection gives an accurate pathological diagnosis because
of the high rate of en bloc resection, irrespective of the tu-
mor size, despite the high incidence of bleeding or perfo-
ration.122 ER is a standard, minimally invasive treatment for
Tis and T1a ESCC.97 The indication of ER for T1b ESCC is
controversial; a study is under way to provide the rationale
to address this issue.123 This study concept is as follows: ER
therapy alone can be effective for patients with a Tis or T1a
tumor with a negative surgical margin and without
lymphatic or venous invasion, but additional treatment,
including surgical resection or chemoradiotherapy (CRT),
should be considered for patients with a T1b tumor and/or
positive surgical margin and/or positive lymphatic/venous
invasion.
Endoscopic surveillance after endoscopic local therapy
for early-stage ESCC should be continued because meta-
chronous ESCC and head and neck SCC can develop, espe-
cially in patients with multiple LVLs.58 Additional ER and/or
ablation may be needed if metachronous early-stage ESCC is
detected. Patients should be evaluated every 3 months in
the ﬁrst year after treatment and every 3 to 6 months in the
second year.97Surgery
Surgery is used widely to obtain locoregional control and
has an important role in the treatment of esophageal cancer.
Transthoracic esophagectomy is one of the most invasive
surgeries. Outcomes appear to be related to the incidence
and management of perioperative complications and seem
to be good in high-volume centers with experienced sur-
geons.124 ESCC is often accompanied by extensive metas-
tasis to lymph nodes in the cervical, thoracic, and abdominal
regions. There is controversy regarding the extent of lymph
node dissection required. In particular, the advantage of a
3-ﬁeld lymphadenectomy over a 2-ﬁeld lymphadenectomy
for ESCC is unclear. A recent meta-analysis of 13 studies
revealed a marked improvement in surgical outcomes after
3-ﬁeld lymphadenectomy compared with 2-ﬁeld lympha-
denectomy, including a higher 5-year rate of survival (haz-
ard ratio, 0.64).125 On the other hand, perioperative
morbidities have been noted, such as a higher prevalence of
anastomotic leakage and a similar prevalence of pulmonary
complications and postoperative vocal cord palsy.125 The
addition of cervical lymph node dissection therefore im-
proves the long-term outcomes of patients compared with
only 2-ﬁeld lymphadenectomy, especially for patients with
thoracic esophageal cancer with positive lymph nodes.
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more invasive procedure.125
To overcome this issue, minimally invasive surgery has
been developed. Magnifying the view from the thoracoscope
makes it possible to perform accurate lymph node dissec-
tion; this technique has been applied to patients with stage I,
II, and III (excluding T4) esophageal cancers. Some evidence
is available on the short-term beneﬁts (shorter hospital
stays as well as lower rates of respiratory complications and
total morbidity) of minimally invasive surgery compared
with open esophagectomy.126,127 Moreover, the rate of
5-year survival after minimally invasive esophagectomy is
similar to that for open esophagectomy.128 A prospective
randomized trial is under way in Japan to prove the non-
inferiority of minimally invasive thoracoscopic esoph-
agectomy to open esophagectomy for thoracic esophageal
cancers.Neoadjuvant and Adjuvant Therapy
Neoadjuvant chemotherapy (in the United Kingdom) or
neoadjuvant CRT (in the United States and France) is per-
formed as standard treatment for locally advanced
ESCC.129,130 However, clinical trials conducted in Europe
and the United States have included a low percentage of
patients with SCC (<50%). Randomized multicenter trials of
patients with stage I/II ESCC that compared neoadjuvant
CRT (cisplatin þ 37-Gy radiation) followed by surgery with
surgery alone showed that neoadjuvant CRT did not in-
crease overall survival.131 However, a recently updated
meta-analysis (24 trials, 4188 patients, 3500 events, 65% of
patients with SCC) provided strong evidence that neo-
adjuvant CRT and chemotherapy increase survival versus
surgery alone (hazard ratios of 0.78 and 0.87, respectively)
in patients with esophageal cancer, although a clear
advantage of neoadjuvant CRT over neoadjuvant chemo-
therapy has not been shown.132 Of note, when limited to the
patients with ESCC included in this meta-analysis, neo-
adjuvant CRT signiﬁcantly increased the chances of survival
versus surgery alone (hazard ratio, 0.80) but not versus
neoadjuvant chemotherapy (hazard ratio, 0.92).132
In Japan, neoadjuvant chemotherapy with cisplatin plus
5-ﬂuorouracil (5-FU) is the standard treatment regimen for
locally advanced (stage II or III, except T4) ESCC.133 This
neoadjuvant chemotherapy increases overall survival and is
regarded as the standard treatment for patients with stage
II or III ESCC (55% survive for 5 years).134 Based on this
background, another intensive neoadjuvant chemothera-
peutic regimen with docetaxel and cisplatin plus 5-FU (DCF)
has been proposed.135 A phase 3 trial is under way to
investigate whether DCF is superior to cisplatin plus 5-FU
and whether cisplatin plus 5-FU with CRT is superior to
cisplatin plus 5-FU alone.136
Interestingly, a German trial reported that the addition
of surgery did not prolong survival of patients with locally
advanced thoracic ESCC (T3-4N0-1M0) who responded to
neoadjuvant chemotherapy followed by CRT.137 In this trial,
a tumor response to neoadjuvant chemotherapy was the
single prognostic factor for overall survival.137 A trial inFrance also reported that the addition of surgery did not
prolong survival of patients with locally advanced thoracic
esophageal cancer (T3-N0-1M0; 89% of patients with SCC)
who responded to induction CRT.138 These results indicate
that good responses to neoadjuvant chemotherapy or CRT
may not require additional surgery.
Deﬁnitive CRT
Because CRT has been reported to be superior to
radiotherapy alone for the treatment of patients with locally
advanced esophageal cancer,139 the concept of deﬁnitive
CRT has emerged. At ﬁrst, deﬁnitive CRT was applied to
inoperable locally advanced (T4) ESCC. Even for T4 ESCC,
deﬁnitive CRT can produce complete remission in 15% to
33% of patients (median survival time of approximately
10 months).140,141
A clinical trial of deﬁnitive CRT, which included patients
with stage II or III ESCC, reported a complete response in
68% of patients and that 37% survived for 5 years.142 This
result was inferior to that of neoadjuvant chemotherapy
followed by surgery (5-year rate of survival, 55%).134
Deﬁnitive CRT for stage II or III ESCC is therefore a
nonsurgical treatment option.
CRT has some problems. First, CRT fails in more than
40% of patients143; the prognosis is poor for these patients,
with more than 50% mortality within 6 months.144 In such
cases, salvage treatment is needed. Second, approximately
10% of patients with complete responses after treatment
with 60-Gy CRT experience late-stage, high-grade toxicity,
including pericarditis, pleural effusion, and radiation pneu-
monitis.145 A dose-escalation study of radiation was con-
ducted to improve local control.146 However, no signiﬁcant
difference was observed in local/regional control of patients
(85% of patients with SCC) treated with cisplatin plus 5-FU
in the 50.4-Gy group versus the 64.8-Gy group.146 Based on
this evidence, the standard radiation dose of deﬁnitive CRT
for ESCC is currently 50 to 50.4 Gy at 1.8 to 2 Gy per
fraction. In addition, the use of the multiple-ﬁeld technique
to reduce the volume of the heart within the radiation ﬁeld
is recommended to prevent late-stage cardiac toxicity.
Salvage Therapy
The diagnosis of local recurrence after CRT should be
conducted promptly and precisely. The median time to local
recurrence after CRT is 9 months.147 Early recurrent tumors
that have achieved complete remission after CRT typically
show a submucosal tumor–like appearance (Figure 6).148
Salvage therapies, including ER and surgery, are
considered for residual or recurrent tumors after deﬁnitive
CRT.149 Salvage ER has been tested on residual and recur-
rent tumors at primary sites after deﬁnitive CRT and
produced positive long-term results without severe com-
plications in patients with superﬁcial failed lesions.150
Recently, photodynamic therapy has been shown to be a
curative option for patients with local failure limited to the
submucosal layer.151 Salvage surgery is aimed at curative
resection for those tumors. However, only patients with
T1N0 or T2N0 ESCC survive for long periods.144 Salvage
Figure 6. Submucosal tumor–like appearance of recurrent ESCC after chemoradiotherapy. (A) Endoscopic image at the initial
diagnosis of ESCC. A large type 2 tumor is seen in the middle thoracic esophagus. (B) Endoscopic image after CRT. Complete
response was achieved by deﬁnitive CRT. (C) Endoscopic image of a submucosal tumor–like recurrent tumor after complete
response of the primary tumor. A submucosal tumor–like lesion was detected on a scar after CRT. (D) Lugol chromoendo-
scopic image of the tumor shown in C. The main part of the lesion was stained by Lugol staining, which indicates that the
surface is covered in normal epithelium. (E) EUS image of the tumor shown in C. A low-echoic mass was found in the sub-
mucosa and in parts of the shallow layer of the muscularis propria.
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ESsurgery has a greater risk of respiratory complications and
anastomotic leakage than planned surgery.144,152 This risk is
associated with ﬁbrous changes in the mediastinum after
radiation and difﬁculties in the anastomosis as a result of
the irradiated gastric tubes.144Chemotherapy for Unresectable Locally
Advanced or Metastatic ESCC
Combinations of cisplatin and 5-FU are commonly used
in chemotherapy for patients with unresectable locally
advanced or metastatic ESCC; this treatment is believed to
be better than the best supportive care.153 Taxanes (doce-
taxel and paclitaxel) have been reported to be effective as
single-agent chemotherapeutics, with response rates of
20% to 34%.154,155 Recently, the 3-drug regimen with DCF
was reported to have a 62% response rate.156 Based on this
result, a randomized controlled phase 3 study is under way
to compare DCF with cisplatin plus 5-FU in patients with
metastatic or recurrent ESCC.157Targeted Therapy
EGFR is one of the most investigated molecular targets in
the ﬁeld of SCC. Cetuximab, a mouse-human monoclonal
immunoglobulin G1 against EGFR, is effective against head
and neck SCC in combination with radiotherapy.158 How-
ever, addition of cetuximab to CRT did not yield a signiﬁcant
survival beneﬁt for esophageal cancer, including ESCC, in a
phase 3 study.159 A phase 3 study of geﬁtinib, a tyrosine
kinase EGFR inhibitor, in patients with ESCC did not showan increase in overall survival.160 There is therefore little
evidence to support EGFR-targeting therapies for ESCC.
Recently, strategies have been developed to target the
programmed cell death protein 1 signaling pathway (PD1-
PDL1).161 Patients whose ESCC was positive for PD1
signaling (43.9%) had signiﬁcantly poorer outcomes than
patients whose ESCC did not have activation of this
signaling pathway.162 On the basis of these data, a clinical
trial is under way to target the PD1-PDL1 pathway in pa-
tients with ESCC who have not responded to standard
chemotherapy.Palliative Care
Some patients with advanced ESCC experience
dysphagia and malnutrition because of esophageal stenosis
and aspiration caused by a ﬁstula.120 To improve these
conditions, palliative care is strongly recommended.
Dysphagia and malnutrition decrease quality of life in
patients with advanced ESCC.163 Radiation therapy palli-
ates dysphagia for several months, but it takes 4 to 6
weeks after treatment for symptoms to improve.164
Instead, a self-expanding metal stent (SEMS) is a safe
and effective treatment for palliation of dysphagia in pa-
tients with ESCC.165 Compared with uncovered SEMSs,
covered SEMSs prevent tumor growth (53% vs 100%)
and reduce restenosis (8% vs 37%)166 Biodegradable
stents have been developed, although their application is
limited because of unknown long-term efﬁcacy.167 In pa-
tients with prior CRT, SEMSs can cause life-threatening
complications.168
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nant esophagorespiratory ﬁstulas. SEMS were shown to
sealed the esophagorespiratory ﬁstula successfully in 80%
(49/61) of patients.169 Patients with successful closure with
SEMSs survived longer than those with unsuccessful closure
(15.1 vs 6.2 weeks).169Future Directions
Alcohol, acetaldehyde associated with alcoholic bever-
ages, and tobacco are esophageal carcinogens that contribute
to the development of ESCC. Polymorphisms in ALDH2 also
contribute to the development of ESCC, particularly in Asian
people. In addition, external and internal risk factors
together contribute to the development of ESCC. An effort is
needed to develop preventive strategies as the next step.
Advances in early detection should encourage the develop-
ment of effective screening systems for high-risk people.
Effective detection of early ESCC allows for the use of
minimally invasive treatments such as ER. Field cancer-
ization should be considered for intensive surveillance in
successfully treated patients. However, for advanced ESCC,
the treatment outcomes leave room for improvement.
Further research is needed to establish techniques for less
invasive surgery; more effective chemotherapy and radio-
therapy are required to increase patient survival. Precision
medicine based on genomic data could lead to new methods
for prevention, diagnosis, and treatment of ESCC.References
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